Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective trial in pateints with Crohn's disease or ulcerative colitis that had moderate to severe active endoscopic disease and treated with infliximab, vedolizumab or ustekinumab

Next Previous
Trial Profile

A prospective trial in pateints with Crohn's disease or ulcerative colitis that had moderate to severe active endoscopic disease and treated with infliximab, vedolizumab or ustekinumab

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms CONSTELLATION

Most Recent Events

  • 15 Jul 2023 Results published in the Gastroenterology
  • 04 Jul 2021 New trial record
  • 23 May 2021 Primary endpoint (Corticosteroid- free deep remission (SFDR) at week 14 defined as HBI 5 in CD and PMS2 in UC and a normal CRP/FC while off corticosteroids.) has been met, as per results presented at the Digestive Disease Week 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top